Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
Roche announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strength...
Henlius celebrated its World R&D Day 2025, under the theme "Collaborate to Create", bringing together senior executives, experts and indust...
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Feldan Therapeutics...
SecondWave Systems, Inc., a clinical stage medical device company developing a novel ultrasound-based treatment for inflammatory disorders, announced tha...
Gennova Biopharmaceuticals Ltd., a pioneering company in mRNA technology and vaccine development, is proud to announce a strategic partnership with the C...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a ...
AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manu...
Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur...
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Ther...
Merck, known as MSD outside of the United States and Canada, announced the opening of a new, $1 billion, 225,000-square-foot facility dedicated to va...
CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and la...
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, a...
Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed fundi...
© 2025 Biopharma Boardroom. All Rights Reserved.
